Breast cancer in the United States: current treatment and diagnosis strategies, risk factors and preventive methods

Dipongkar R. Sobuj; M. Rokibul H. Bhuiyan; Tamanna Rashid; Saiful I. Arif; M. Rakib R. Rana; M. Maniruzzaman; Sabina Akter; M. Sadikuj Jaman

doi:10.18203/2394-6040.ijcmph20254069

Authors

Dipongkar R. Sobuj Department of Chemistry and Biochemistry, Lamar University, Beaumont, Texas
M. Rokibul H. Bhuiyan Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh
Tamanna Rashid Department of Chemistry and Biochemistry, Lamar University, Beaumont, Texas
Saiful I. Arif Jahurul Islam Medical College, Bangladesh
M. Rakib R. Rana Department of Pharmacy, School of Science and Technology, Varendra University, Rajshahi, Bangladesh
M. Maniruzzaman Department of Pharmacy, School of Science and Technology, Varendra University, Rajshahi, Bangladesh
Sabina Akter Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh; Department of Biochemistry and Molecular Biology, Patuakhali Science and Technology University, Patuakhali, Bangladesh
M. Sadikuj Jaman Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20254069

Keywords:

Breast cancer, Risk factors, Epidemiology, Treatment, Prevention, Early detection

Abstract

Breast cancer is the most frequently diagnosed cancer in women and remains a leading cause of cancer-related deaths worldwide. Its burden affects women physically, mentally, and socially, making it a major public health concern. The development and outcome of the disease are influenced by several risk factors, including age, family history, genetic alterations, reproductive history, lifestyle behaviors such as physical inactivity, obesity, alcohol use, smoking, and exposure to radiation. In the United States, recent evidence indicates that breast cancer among younger women (ages 20–49) is rising, with variations by race, ethnicity, tumor stage, and hormone receptor status. Younger patients often face worse prognoses than older women. Treatment requires a multidisciplinary approach, guided by tumor biology, stage, and molecular markers. For early-stage disease, breast-conserving surgery with radiotherapy or mastectomy remains the standard, often combined with adjuvant systemic therapy based on nodal involvement, hormone receptor, and HER2 status. In metastatic disease, the focus shifts to prolonging survival and maintaining quality of life. Advances in chemotherapy, radiotherapy, endocrine therapy, targeted therapy, immunotherapy, and gene-based treatments continue to expand options. However, disparities in access and outcomes persist.

Metrics

Metrics Loading ...

References

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. DOI: https://doi.org/10.3322/caac.21763

Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019;11:151-64. DOI: https://doi.org/10.2147/BCTT.S176070

Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018;39(5):593-620. DOI: https://doi.org/10.1002/humu.23406

Jaman MS, Sayeed MA. Ellagic acid, sulforaphane, and ursolic acid in the prevention and therapy of breast cancer: current evidence and future perspectives. Breast Cancer. 2018;25(5):517-28. DOI: https://doi.org/10.1007/s12282-018-0866-4

Colditz GA, Bohlke K, Berkey CS. Breast cancer risk accumulation starts early: prevention must also. Breast Cancer Res Treat. 2014;145(3):567-79. DOI: https://doi.org/10.1007/s10549-014-2993-8

DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438-51. DOI: https://doi.org/10.3322/caac.21583

Johnson RH, Anders CK, Litton JK, Ruddy KJ, Bleyer A. Breast cancer in adolescents and young adults. Pediatr Blood Cancer. 2018;65(12):e27397. DOI: https://doi.org/10.1002/pbc.27397

Daly B, Olopade OI. A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and how to intervene. CA Cancer J Clin. 2015;65(3):221-38. DOI: https://doi.org/10.3322/caac.21271

Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-41. DOI: https://doi.org/10.1056/NEJMoa022152

Boughey JC, Attai DJ, Chen SL, Cody HS, Dietz JR, Feldman SM, et al. Contralateral prophylactic mastectomy consensus statement from the American Society of Breast Surgeons. Ann Surg Oncol. 2016;23(10):3100-5. DOI: https://doi.org/10.1245/s10434-016-5443-5

Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-75. DOI: https://doi.org/10.1001/jama.2011.90

Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24(13):2028-37. DOI: https://doi.org/10.1200/JCO.2005.04.3273

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432-44. DOI: https://doi.org/10.1016/S0140-6736(11)61625-5

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-72. DOI: https://doi.org/10.1016/S0140-6736(13)62422-8

Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7):1497-508. DOI: https://doi.org/10.1093/annonc/mdy127

Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147-59. DOI: https://doi.org/10.1056/NEJMoa1612645

Jaman MS, Alam MS, Rezwan MS, Islam MR, Husna AU, Sayeed MA. Comparison of total antioxidant activity between fresh and commercial mango juices available in Bangladesh. GSC Biol Pharm Sci. 2017;1(2):26-33. DOI: https://doi.org/10.30574/gscbps.2017.1.2.0045

Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med. 1995;333(22):1444-55. DOI: https://doi.org/10.1056/NEJM199511303332202

Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513-20. DOI: https://doi.org/10.1056/NEJMoa0906260

Bhuiyan MRH, Maniruzzaman M, Akter S, Rashid MHB, Ehasanullah M, Jaman MS. Assessment of antioxidant and antineoplastic activities of Blumea lacera (Burn. F) leaves. Int Acad J Appl Bio-Med Sci. 2022;3(2).

EBCTCG (Early Breast Cancer Trialists' Collaborative Group); McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomized trials. Lancet. 2014;383(9935):2127-35. DOI: https://doi.org/10.1016/S0140-6736(14)60488-8

Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317-27. DOI: https://doi.org/10.1056/NEJMoa1415369

Bhuiyan MRH, Maniruzzaman M, Akter S, Mehjabin S, Rana MRR, Jaman MS. Drug promising effect for diabetic mice of Carica papaya leaves. Eur J Pharm Res. 2022;2(3):1-5. DOI: https://doi.org/10.24018/ejpharma.2022.2.3.47

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-16. DOI: https://doi.org/10.1016/S0140-6736(12)61963-1

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371(2):107-18. DOI: https://doi.org/10.1056/NEJMoa1404037

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-41. DOI: https://doi.org/10.1016/S1470-2045(10)70257-6

Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-84. DOI: https://doi.org/10.1200/JCO.2017.73.7585

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-34. DOI: https://doi.org/10.1056/NEJMoa1413513

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108-21. DOI: https://doi.org/10.1056/NEJMoa1809615

Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449-59. DOI: https://doi.org/10.1056/NEJMoa1709919

Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. 2015;314(15):1599-614. DOI: https://doi.org/10.1001/jama.2015.12783

Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm-Vélez M, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008;299(18):2151-63. DOI: https://doi.org/10.1001/jama.299.18.2151

Maniruzzaman M, Bhuiyan MRH, Jaman MS, Haque MS. MicroRNA dynamics, PTEN/PI3K/AKT signaling, and their relationship to breast cancer: prospects for pharmaceuticals and natural product application. Breast Cancer Res Treat. 2025;209(3):467-85. DOI: https://doi.org/10.1007/s10549-024-07600-7

Dillon MF, McDermott EW, Quinn CM, O’Doherty A, O’Higgins N, Hill AD. Diagnostic accuracy of core biopsy for ductal carcinoma in situ and its implications for surgical practice. J Clin Pathol. 2006;59(7):740-3. DOI: https://doi.org/10.1136/jcp.2005.034330

Jaman MS, Maniruzzaman M, Rana MRR, Bhuyan MRH, Akter L, Ahmad S, et al. Overall summary of Gulf country employees from Bangladesh, preliminary evaluation for abnormal kidney, liver, and virally infected individuals using low-cost tests like CBC parameters. Chem Sci Int J. 2024;33(4):19-33. DOI: https://doi.org/10.9734/CSJI/2024/v33i4903

Willems SM, van Deurzen CHM, van Diest PJ. Diagnosis of breast lesions: fine-needle aspiration cytology or core needle biopsy? A review. J Clin Pathol. 2012;65(4):287-92. DOI: https://doi.org/10.1136/jclinpath-2011-200410

Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2016;164(4):244-55. DOI: https://doi.org/10.7326/M15-0969

Bhuiyan MRH, Mamun AA, Sharker B, Jaman MS. Anticancer activity and therapeutic uses of catechins on breast, prostate and lung cancer: future perspective and clinical proofs. J Clin Cas Rep, Med Imag Heal Sci. 2023;3(3).

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet. 2002;360(9328):187-95. DOI: https://doi.org/10.1016/S0140-6736(02)09454-0

Jaman S, Islam N, Maniruzzaman M, Hossain F, Bhuiyan RH, Emaul N. Preventive and therapeutic effect of ellagic acid, sulforaphane and ursolic acid on colon cancer: from cellular response to molecular mechanism of action with future perspectives. Int J Clin Med Case Rep. 2023;1:1-20.

Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(1):77-102. DOI: https://doi.org/10.6004/jnccn.2021.0001

Jaman MS, Mamun AA, Sharker B, Maniruzzaman M, Rana MRR, Hasan MN, Bhuiyan MRH. Curcumin, diallyl sulphide, quercetin and gallic acid uses as anticancer and therapeutic agents for breast cancer: current strategies and future perspectives. Eur J Med Health Sci. 2023;5(3):32-48. DOI: https://doi.org/10.24018/ejmed.2023.5.3.1699

Jaman S, Sawgat R, Alam S, Islam R, Husna AU, Sayeed MA. Association of mean platelet volume and platelet distribution width with HbA1c. J Endocrinol Diab. 2017;4(4):1-6. DOI: https://doi.org/10.15226/2374-6890/4/4/00183

Jaman MS, Rahman MS, Swarna RR, Mahato J, Miah MM, Ayshasiddeka M. Diabetes and red blood cell parameters. Ann Clin Endocrinol Metabol. 2018;2:001-9. DOI: https://doi.org/10.29328/journal.acem.1001004